{"id":"W2588876159","doi":"10.1182/blood.v128.22.1110.1110","title":"Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Brentuximab vedotin; Oncology; Autologous stem-cell transplantation; Cohort; Progression-free survival; Clinical endpoint; Transplantation; Lymphoma; Surgery; Chemotherapy; Clinical trial; Hodgkin lymphoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001911044,0.0007228043,0.001214127,0.0002727539,0.0004027669,0.0009495056,0.0005613784,0.0007350105,0.00276332],"category_scores_gemma":[0.001121949,0.0003855011,0.001442183,0.0002805644,0.0003545188,0.0006717293,0.0003952259,0.001513407,0.0005979385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008252921,"about_ca_system_score_gemma":0.0009447928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009593866,"about_ca_topic_score_gemma":0.002641074,"domain_scores_codex":[0.9995128,0.0002186411,0.00003555093,0.000108145,0.00006299454,0.00006193438],"domain_scores_gemma":[0.9990928,0.0001439356,0.0002219198,0.000105578,0.00009696012,0.0003388808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7061497,0.04287403,0.08059294,0.001222887,0.004813391,0.0004058159,0.0004629318,0.001945397,0.02871259,0.0002054155,0.006356801,0.1262581],"study_design_scores_gemma":[0.3759699,0.4023554,0.204948,0.00007680774,0.003131036,0.0006002671,0.0001092744,0.002333662,0.004098896,0.0001889669,0.006110265,0.00007752614],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947979,0.001334344,0.0002173306,0.0001661898,0.00005246187,0.0009073264,0.001441121,0.00004961928,0.001033579],"genre_scores_gemma":[0.993239,0.0004534294,0.0008969379,0.0006049558,0.0001054628,0.00117642,0.002604643,0.00001249577,0.0009065605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00276332,"threshold_uncertainty_score":0.01010668,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009844112837785985,"score_gpt":0.2363699067996585,"score_spread":0.2265257939618725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}